Yoel Bakas sits down with Jeff Siupik, a healthcare executive with 35 years in oncology operations and 25 years in oncology leadership. Jeff has put in eight to ten linear accelerators across his career, led oncology programs through every reimbursement shift since the early 1990s, and currently oversees operations across a multi-program system.

The conversation walks through the actual job of an oncology administrator in 2026.

The balance between growth and expense control. Why P&L looks worse before it looks better when a program is in growth mode, and what most administrators are explaining to finance committees right now.

How to read your operation when the metrics look green. The stoplight framework Jeff uses for evaluating efficiency, and why a green department can still have staff running in the red line of mental capacity.

The disconnect between the C-suite and the clinical team. Where volume responsibility actually belongs in a healthy program, and where leaders most often misallocate it.

Capital decisions in radiation oncology. What separates the programs that get capital right from the ones that do not. Service contracts, software licensing, the ongoing-cost trap, and creative offsets like block leases.

AI in oncology operations. A pragmatic take on what AI is actually doing in cancer programs right now versus what is being pitched. Where AI creates time, where it slows things down, and how to think about the patient-side implications.

A worked example of how a leadership team handles competing capital requests across service lines, and why “every specialty feels their request is the highest priority” is the room every administrator is in.

Yoel and Jeff have known each other for over a decade across the vendor and operator sides of radiation oncology. This is operator-thinking from someone who has lived the job.

22 minutes. Worth the time for any administrator, medical director, or system executive running an oncology program in 2026.

Medsolve Dynamics: medsolvedynamics.com Reach the team: [email protected]

#RadiationOncology #OncologyLeadership #CapitalStrategy #HealthcareExecutive #OncologyOperations

Hiring and retention decisions are landing on the same desks as AI tool decisions, often in the same week. After 20 years on the vendor side, here is the discipline most programs are missing: the same questions you would ask of any capital line, applied to the people on the team and the tools being sold to replace them. medsolvedynamics.com | [email protected]

#RadiationOncology #OncologyLeadership #StaffPlanning #FinancialStrategy

From the Medsolve Dynamics conversation with Heather Turner, radiation oncology operator with 14 years from therapist to director. The contracts are not the problem. The autopilot is. medsolvedynamics.com | [email protected]

#RadiationOncology #ServiceContracts #VendorNegotiation #OncologyLeadership

The economic case for a LINAC purchase rarely fails at signature. It fails in years two through eight, when the bundled add-ons start collecting service contracts and software renewals. After 20 years on the vendor side, here is what the inside of that conversation looks like, and why bundles are designed exactly this way. medsolvedynamics.com | [email protected]

#RadiationOncology #LINAC #CapitalStrategy #VendorNegotiation #OncologyLeadership

Most oncology capital and service negotiations are decided before anyone sits down. Vendor teams map your budget range, rehearse responses to your objections, and identify pricing flexibility they never surface unless you ask the right way.

Yoel Bakas spent 20+ years on the vendor side of those conversations at Varian, GE HealthCare, ViewRay, and Mevion before founding Medsolve Dynamics. In this short, he lays out what actually happens in the prep call two days before your meeting, and why harder negotiating rarely changes the outcome.

Medsolve Dynamics is a vendor-neutral oncology consulting firm built for programs navigating margin pressure, capital scrutiny, and AI overload.

medsolvedynamics.com [email protected]

#RadiationOncology #CapitalStrategy #VendorNegotiation #LINAC #OncologyLeadership

After 20 years on the vendor side of oncology at GE HealthCare, ViewRay, and Varian, Yoel Bakas launched Medsolve Dynamics to work from your program side. In this episode, he walks through what Medsolve actually does: capital strategy on LINAC and theranostics purchases, service contract renegotiation before escalator clauses compound, financial case building for theranostics and benign disease service lines before capital is committed, and AI and software evaluation on clinical value and ROI rather than vendor claims. If you have a capital decision, a service contract renewal, a new service line, or an AI evaluation in front of you right now, this is who Medsolve was built for. LINAC capital strategy, oncology vendor negotiation, radiation oncology service contracts, theranostics service line, benign disease radiation therapy, AI in oncology, hospital operations. medsolvedynamics.com | [email protected]

Most oncology service contracts renew automatically unless a specific window is used to renegotiate. Yoel Bakas, founder of Medsolve Dynamics, walks through the specific mechanics of a renewal clock that most program administrators miss until it has already closed — and what a single overlooked provision on page 7 cost one cancer program. Twenty years on the vendor side of oncology means knowing where the escalators, auto-renewals, and quiet cost increases are written into the fine print, and where the leverage lives before the next signature. LINAC service contracts, oncology service renewal, radiation oncology operations, capital strategy. medsolvedynamics.com | [email protected]

The conversation highlights the pitfalls of AI procurement, the consequences of procurement failure, misleading claims in AI sales, and key questions for procurement. It emphasizes the importance of considering adoption requirements and the impact on workflow when purchasing AI solutions.

Takeaways

• Procurement failure
• Adoption requirements

medsolvedynamics.com

[email protected]

The conversation explores the critical question of whether decisions hold up at 80% of the current reimbursement, emphasizing the importance of considering this in every capital decision and service renewal.

Takeaways

• Financial decisions must consider sustainability at 80% reimbursement
• Every purchase decision should be evaluated based on sustainability at 80% reimbursement

medsolvedynamics.com

[email protected]

A physicist's excitement about a new tool without a clear problem to solve.

Takeaways

• Tool adoption without a clear problem
• The allure of new technology

medsolvedynamics.com

[email protected]